Circulating biomarkers of tryptophan and the kynurenine pathway and lung cancer risk
Autor: | Kjell Grankvist, Eva Ardanaz Aicua, Paolo Vineis, Angelika Wientzek, Tilman Kuehn, Marc J. Gunter, Françoise Clavel-Chapelon, Anouar Fanidi, Ruth C. Travis, Mattias Johansson, Øivind Midttun, Elisabete Weiderpass, Elio Riboli, Nicholas J. Wareham, María Dolores Chirlaque, Guy Fagherazzi, Antonio Agudo, Caroline L Relton, Mikael Johansson, María José Sánchez, Marie-Christine Boutron-Ruault, Stein Emil Vollset, Paul Brennan, Rudolf Kaaks, H. Bas Bueno-de-Mesquita, José Ramón Quirós, Pagona Lagiou, Claudia Agnoli, Shu Chun Chuang, Domenico Palli, Antonia Trichopoulou, Michael J. Seckl, Petra H.M. Peeters, Alessio Naccarati, Heiner Boeing, Per Magne Ueland, Rosario Tumino, Dimitrios Trichopoulos |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2014 |
Předmět: |
Adult
Male Kynurenine pathway Lung Neoplasms Epidemiology Cohort Studies chemistry.chemical_compound Risk Factors Surveys and Questionnaires Biomarkers Tumor Medicine Humans Prospective Studies Prospective cohort study Lung cancer Kynurenine Aged business.industry Case-control study Tryptophan Tryptophan Metabolism Middle Aged medicine.disease Europe Circulating biomarkers Oncology chemistry Case-Control Studies Immunology Female business |
Zdroj: | Cancer epidemiology, biomarkers and prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 23(3) |
ISSN: | 1538-7755 1055-9965 |
Popis: | Background: Imbalances in tryptophan metabolism have been linked to cancer-related immune escape and implicated in several cancers, including lung cancer. Methods: We conducted a nested case–control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) that included 893 incident lung cancer cases and 1,748 matched controls. Circulating levels of tryptophan and six of its metabolites were measured and evaluated in relation to lung cancer risk. Results: Tryptophan (Ptrend = 2 × 10−5) and the kynurenine/tryptophan ratio (KTR; Ptrend = 4 × 10−5) were associated with lung cancer risk overall after adjusting for established risk factors. The ORs comparing the fifth and first quintiles (OR5th vs. 1st) were 0.52 [95% confidence interval (CI), 0.37–0.74] for tryptophan and 1.74 (95% CI, 1.24–2.45) for KTR. After adjusting for plasma methionine (available from previous work, which was strongly correlated with tryptophan), the associations of tryptophan (adjusted Ptrend = 0.13) and KTR (Ptrend = 0.009) were substantially attenuated. KTR was positively associated with squamous cell carcinoma, the OR5th vs. 1st being 2.83 (95% CI, 1.62–4.94, Ptrend = 3 × 10−5) that was only marginally affected by adjusting for methionine. Conclusions: This study indicates that biomarkers of tryptophan metabolism are associated with subsequent lung cancer risk. Although this result would seem consistent with the immune system having a role in lung cancer development, the overall associations were dependent on methionine, and further studies are warranted to further elucidate the importance of these metabolites in lung cancer etiology. Impact: This is the first prospective study investigating the tryptophan pathway in relation to lung cancer risk. Cancer Epidemiol Biomarkers Prev; 23(3); 461–8. ©2013 AACR. |
Databáze: | OpenAIRE |
Externí odkaz: |